Symbols / CLLS Stock $3.91 -1.76% Cellectis S.A.
CLLS (Stock) Chart
About
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Stock Fundamentals
Scroll to Statements| Market Cap | 393.31M | Enterprise Value | 169.22M | Income | -67.59M | Sales | 79.59M | Book/sh | 1.05 | Cash/sh | 2.84 |
| Dividend Yield | — | Payout | 0.00% | Employees | 224 | IPO | — | P/E | — | Forward P/E | -6.31 |
| PEG | — | P/S | 4.94 | P/B | 3.73 | P/C | — | EV/EBITDA | -7.78 | EV/Sales | 2.13 |
| Quick Ratio | 1.59 | Current Ratio | 1.62 | Debt/Eq | 114.22 | LT Debt/Eq | — | EPS (ttm) | -0.67 | EPS next Y | -0.62 |
| EPS Growth | — | Revenue Growth | -19.50% | Earnings | 2026-05-18 | ROA | -5.84% | ROE | -65.33% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -142.14% | Profit Margin | -84.92% | Shs Outstand | 72.59M | Shs Float | 46.68M | Short Float | 0.65% |
| Short Ratio | 6.71 | Short Interest | — | 52W High | 5.48 | 52W Low | 1.33 | Beta | 2.71 | Avg Volume | 45.31K |
| Volume | 9.82K | Target Price | $7.25 | Recom | Buy | Prev Close | $3.98 | Price | $3.91 | Change | -1.76% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-14 | reit | Citizens | Market Outperform → Market Outperform | $8 |
| 2025-12-23 | init | Clear Street | — → Buy | $9 |
| 2025-10-17 | main | Barclays | Overweight → Overweight | $8 |
| 2025-05-13 | main | Barclays | Overweight → Overweight | $4 |
| 2024-11-05 | main | Barclays | Overweight → Overweight | $5 |
| 2024-06-12 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2024-05-31 | reit | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2023-11-01 | reit | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2023-08-08 | reit | Oppenheimer | Outperform → Outperform | $11 |
| 2023-08-07 | reit | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2023-04-05 | main | Citigroup | — → Buy | $16 |
| 2023-03-13 | main | Oppenheimer | — → Outperform | $13 |
| 2023-03-13 | reit | JMP Securities | — → Market Outperform | $6 |
| 2023-01-19 | main | JMP Securities | — → Market Outperform | $6 |
| 2022-05-24 | main | Goldman Sachs | — → Sell | $2 |
| 2022-05-18 | up | Baird | Neutral → Outperform | — |
| 2022-05-13 | main | Barclays | — → Overweight | $7 |
| 2022-01-06 | down | Wells Fargo | Overweight → Equal-Weight | $16 |
| 2021-11-30 | init | JMP Securities | — → Market Outperform | $20 |
| 2021-10-08 | down | Baird | Outperform → Neutral | $10 |
- Cellectis says its leukemia cell therapy hit 100% response in target group - Stock Titan hu, 19 Mar 2026 07
- Cellectis (NASDAQ:CLLS) Shares Pass Below 200-Day Moving Average - Time to Sell? - MarketBeat Wed, 22 Apr 2026 08
- Is Cellectis (CLLS) Stock Stable Now | Price at $3.45, Down 2.82% - Social Flow Trades - Cổng thông tin điện tử tỉnh Tây Ninh hu, 09 Apr 2026 07
- Should I Buy Cellectis (CLLS) Stock Now | Price at $3.50, Up 2.64% - Short Setup - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Sat, 18 Apr 2026 12
- Is Cellectis (CLLS) Stock Testing Support | Price at $3.44, Up 0.88% - Pro Trader Recommendations - UBND thành phố Hải Phòng Mon, 06 Apr 2026 07
- CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News - GuruFocus Fri, 17 Oct 2025 07
- Cellectis had 100.6M shares and 106M voting rights on March 31 - Stock Titan ue, 07 Apr 2026 07
- CLLS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Sat, 18 Apr 2026 12
- Cellectis (NASDAQ:CLLS) Given Market Outperform Rating at Citizens Jmp - MarketBeat ue, 14 Apr 2026 07
- Most patients stayed outpatient as cema-cel hit 58.3% MRD negativity - Stock Titan Mon, 13 Apr 2026 07
- CLLS Should I Buy - Intellectia AI Sat, 18 Apr 2026 12
- Cellectis lists 100,590,994 shares, 105,825,561 voting rights - Stock Titan Wed, 04 Mar 2026 08
- Cema-cel data lift Cellectis (NASDAQ: CLLS) allogeneic CAR-T ambitions - Stock Titan Mon, 13 Apr 2026 20
- Cellectis (NASDAQ: CLLS) schedules Q4 and full-year 2025 earnings call - Stock Titan hu, 12 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
72.95
+75.76%
|
41.51
+5397.48%
|
0.76
-96.06%
|
19.17
|
| Operating Revenue |
|
72.95
+75.76%
|
41.51
+5397.48%
|
0.76
-96.06%
|
19.17
|
| Cost Of Revenue |
|
9.80
+6.70%
|
9.18
+23.76%
|
7.42
-12.55%
|
8.48
|
| Reconciled Cost Of Revenue |
|
9.80
+6.70%
|
9.18
+23.76%
|
7.42
-12.55%
|
8.48
|
| Gross Profit |
|
63.15
+95.37%
|
32.32
+585.05%
|
-6.66
-162.36%
|
10.69
|
| Operating Expense |
|
96.23
+4.73%
|
91.88
+1.37%
|
90.64
-9.68%
|
100.35
|
| Research And Development |
|
93.52
+3.29%
|
90.54
+3.30%
|
87.65
-10.11%
|
97.50
|
| Selling General And Administration |
|
8.60
+2.09%
|
8.42
+3.71%
|
8.12
-8.72%
|
8.89
|
| Selling And Marketing Expense |
|
—
|
—
|
—
|
3.11
|
| General And Administrative Expense |
|
8.60
+2.09%
|
8.42
+3.71%
|
8.12
-8.72%
|
8.89
|
| Salaries And Wages |
|
7.68
+2.51%
|
7.49
+1.52%
|
7.38
-3.82%
|
7.67
|
| Other Gand A |
|
0.92
-1.29%
|
0.93
+25.61%
|
0.74
-39.56%
|
1.22
|
| Other Operating Expenses |
|
-7.28
+14.94%
|
-8.56
-19.94%
|
-7.14
+9.99%
|
-7.93
|
| Total Expenses |
|
106.03
+4.91%
|
101.06
+3.06%
|
98.06
-9.90%
|
108.84
|
| Operating Income |
|
-33.08
+44.46%
|
-59.55
+38.80%
|
-97.30
-8.52%
|
-89.67
|
| Total Operating Income As Reported |
|
-33.08
+44.46%
|
-59.55
+38.79%
|
-97.30
-8.52%
|
-89.67
|
| EBITDA |
|
-39.85
-321.13%
|
-9.46
+89.79%
|
-92.64
-21.29%
|
-76.38
|
| Normalized EBITDA |
|
-3.52
+87.63%
|
-28.43
+62.73%
|
-76.28
+7.46%
|
-82.44
|
| Reconciled Depreciation |
|
20.06
+1.09%
|
19.85
+7.14%
|
18.52
+0.48%
|
18.43
|
| EBIT |
|
-59.91
-104.41%
|
-29.31
+73.63%
|
-111.16
-17.24%
|
-94.81
|
| Total Unusual Items |
|
-36.33
-291.54%
|
18.97
+216.00%
|
-16.35
-369.83%
|
6.06
|
| Total Unusual Items Excluding Goodwill |
|
-36.33
-291.54%
|
18.97
+216.00%
|
-16.35
-369.83%
|
6.06
|
| Net Income |
|
-67.59
-83.87%
|
-36.76
+63.62%
|
-101.06
+4.79%
|
-106.14
|
| Pretax Income |
|
-68.02
-85.02%
|
-36.76
+68.44%
|
-116.47
-18.12%
|
-98.60
|
| Net Non Operating Interest Income Expense |
|
1.39
-63.63%
|
3.83
+236.02%
|
-2.81
+81.25%
|
-14.99
|
| Interest Expense Non Operating |
|
8.11
+8.77%
|
7.45
+40.44%
|
5.31
+40.14%
|
3.79
|
| Net Interest Income |
|
1.39
-63.63%
|
3.83
+236.02%
|
-2.81
+81.25%
|
-14.99
|
| Interest Expense |
|
8.11
+8.77%
|
7.45
+40.44%
|
5.31
+40.14%
|
3.79
|
| Interest Income Non Operating |
|
9.50
-15.78%
|
11.28
+212.06%
|
3.61
+222.68%
|
1.12
|
| Interest Income |
|
9.50
-15.78%
|
11.28
+212.06%
|
3.61
+222.68%
|
1.12
|
| Other Income Expense |
|
-36.33
-291.54%
|
18.97
+216.00%
|
-16.35
-369.83%
|
6.06
|
| Gain On Sale Of Security |
|
-36.33
-291.54%
|
18.97
+216.00%
|
-16.35
-369.83%
|
6.06
|
| Tax Provision |
|
-0.42
|
0.00
-100.00%
|
0.37
+326.44%
|
0.09
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.23
|
0.00
+100.00%
|
-4.09
-369.83%
|
1.51
|
| Net Income Including Noncontrolling Interests |
|
-67.59
-83.87%
|
-36.76
+66.10%
|
-108.44
+4.90%
|
-114.03
|
| Net Income From Continuing Operation Net Minority Interest |
|
-67.59
-83.87%
|
-36.76
+66.41%
|
-109.45
-20.55%
|
-90.79
|
| Net Income From Continuing And Discontinued Operation |
|
-67.59
-83.87%
|
-36.76
+63.62%
|
-101.06
+4.79%
|
-106.14
|
| Net Income Continuous Operations |
|
-67.59
-83.87%
|
-36.76
+68.54%
|
-116.83
-18.39%
|
-98.69
|
| Net Income Discontinuous Operations |
|
0.00
|
0.00
-100.00%
|
8.39
+154.69%
|
-15.35
|
| Minority Interests |
|
0.00
|
0.00
-100.00%
|
7.38
-6.46%
|
7.89
|
| Normalized Income |
|
-31.49
+43.50%
|
-55.73
+42.66%
|
-97.19
-1.94%
|
-95.34
|
| Net Income Common Stockholders |
|
-67.59
-83.87%
|
-36.76
+63.62%
|
-101.06
+4.79%
|
-106.14
|
| Diluted EPS |
|
-0.67
-63.41%
|
-0.41
+76.84%
|
-1.77
+24.03%
|
-2.33
|
| Basic EPS |
|
-0.67
-63.41%
|
-0.41
+76.84%
|
-1.77
+24.03%
|
-2.33
|
| Basic Average Shares |
|
100.28
+10.72%
|
90.57
+58.85%
|
57.01
+25.16%
|
45.55
|
| Diluted Average Shares |
|
100.28
+10.72%
|
90.57
+58.85%
|
57.01
+25.16%
|
45.55
|
| Diluted NI Availto Com Stockholders |
|
-67.59
-83.87%
|
-36.76
+63.62%
|
-101.06
+4.79%
|
-106.14
|
| Depreciation Amortization Depletion Income Statement |
|
1.40
-5.80%
|
1.48
-26.29%
|
2.01
+6.62%
|
1.89
|
| Depreciation And Amortization In Income Statement |
|
1.40
-5.80%
|
1.48
-26.29%
|
2.01
+6.62%
|
1.89
|
| Other Taxes |
|
—
|
—
|
-6.58
-0.55%
|
-6.55
|
| Total Other Finance Cost |
|
—
|
—
|
1.12
-90.92%
|
12.33
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
324.72
-15.34%
|
383.54
+14.74%
|
334.27
+27.97%
|
261.22
|
| Current Assets |
|
236.25
-17.70%
|
287.07
+23.20%
|
233.01
+62.02%
|
143.81
|
| Cash Cash Equivalents And Short Term Investments |
|
208.66
-19.84%
|
260.31
+27.72%
|
203.81
+108.62%
|
97.70
|
| Cash And Cash Equivalents |
|
61.53
-57.05%
|
143.25
+4.79%
|
136.71
+52.25%
|
89.79
|
| Cash Equivalents |
|
15.62
-85.85%
|
110.34
+100.61%
|
55.00
+121.97%
|
24.78
|
| Cash Financial |
|
45.91
+39.50%
|
32.91
-59.72%
|
81.71
+25.68%
|
65.01
|
| Other Short Term Investments |
|
147.13
+25.69%
|
117.06
+74.43%
|
67.11
+748.70%
|
7.91
|
| Receivables |
|
25.32
+9.90%
|
23.04
-0.40%
|
23.13
+31.61%
|
17.57
|
| Accounts Receivable |
|
14.40
+114.45%
|
6.71
+1079.96%
|
0.57
-26.30%
|
0.77
|
| Gross Accounts Receivable |
|
14.40
+114.45%
|
6.71
+1079.96%
|
0.57
-26.30%
|
0.77
|
| Allowance For Doubtful Accounts Receivable |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Other Receivables |
|
0.09
|
—
|
—
|
—
|
| Taxes Receivable |
|
10.83
-33.65%
|
16.32
-27.65%
|
22.56
+34.28%
|
16.80
|
| Inventory |
|
—
|
—
|
—
|
0.00
|
| Prepaid Assets |
|
1.93
-43.58%
|
3.43
-40.03%
|
5.72
-8.29%
|
6.23
|
| Current Deferred Assets |
|
—
|
—
|
—
|
0.54
|
| Assets Held For Sale Current |
|
—
|
—
|
0.00
-100.00%
|
21.77
|
| Other Current Assets |
|
0.33
+10.74%
|
0.30
-13.62%
|
0.34
-35.87%
|
0.54
|
| Total Non Current Assets |
|
88.48
-8.29%
|
96.48
-4.73%
|
101.27
-13.75%
|
117.41
|
| Net PPE |
|
62.45
-17.69%
|
75.86
-18.20%
|
92.74
-14.05%
|
107.90
|
| Gross PPE |
|
176.04
+5.26%
|
167.24
-0.54%
|
168.16
+2.77%
|
163.62
|
| Accumulated Depreciation |
|
-113.59
-24.31%
|
-91.38
-21.17%
|
-75.42
-35.34%
|
-55.72
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
20.92
+15.33%
|
18.14
-2.18%
|
18.54
+4.52%
|
17.74
|
| Buildings And Improvements |
|
53.75
+5.57%
|
50.91
-1.83%
|
51.86
+4.94%
|
49.42
|
| Machinery Furniture Equipment |
|
5.17
+1.29%
|
5.10
+2.55%
|
4.97
+1.20%
|
4.91
|
| Construction In Progress |
|
1.36
+632.80%
|
0.19
-85.37%
|
1.27
+33.51%
|
0.95
|
| Other Properties |
|
94.84
+2.08%
|
92.91
+1.53%
|
91.50
+1.01%
|
90.59
|
| Goodwill And Other Intangible Assets |
|
0.54
-52.02%
|
1.11
+65.92%
|
0.67
-6.41%
|
0.72
|
| Other Intangible Assets |
|
0.54
-52.02%
|
1.11
+65.92%
|
0.67
-6.41%
|
0.72
|
| Investments And Advances |
|
5.09
-32.35%
|
7.52
-4.23%
|
7.85
-10.67%
|
8.79
|
| Non Current Deferred Assets |
|
0.38
+0.00%
|
0.38
|
—
|
—
|
| Non Current Deferred Taxes Assets |
|
0.38
+0.00%
|
0.38
|
—
|
—
|
| Other Non Current Assets |
|
20.02
+72.70%
|
11.60
+1159600.00%
|
-0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
248.82
-1.46%
|
252.51
+1.18%
|
249.57
+84.49%
|
135.28
|
| Current Liabilities |
|
145.75
-12.34%
|
166.27
+7.17%
|
155.14
+146.28%
|
62.99
|
| Payables And Accrued Expenses |
|
28.12
+2.23%
|
27.51
-3.26%
|
28.44
-16.20%
|
33.94
|
| Payables |
|
17.36
-7.08%
|
18.68
-2.04%
|
19.07
-22.21%
|
24.51
|
| Accounts Payable |
|
17.28
-7.43%
|
18.66
-2.12%
|
19.07
-11.13%
|
21.46
|
| Current Accrued Expenses |
|
10.77
+21.93%
|
8.83
-5.74%
|
9.37
-0.56%
|
9.42
|
| Employee Benefits |
|
1.33
+19.19%
|
1.11
-49.32%
|
2.20
-7.95%
|
2.39
|
| Total Tax Payable |
|
0.08
+400.00%
|
0.02
|
0.00
-100.00%
|
3.06
|
| Current Debt And Capital Lease Obligation |
|
11.79
-10.85%
|
13.23
-3.21%
|
13.66
+6.38%
|
12.84
|
| Current Debt |
|
4.09
-15.51%
|
4.84
-6.22%
|
5.16
+3.82%
|
4.97
|
| Other Current Borrowings |
|
4.09
-15.51%
|
4.84
-6.22%
|
5.16
+3.82%
|
4.97
|
| Current Capital Lease Obligation |
|
7.70
-8.16%
|
8.38
-1.38%
|
8.50
+8.00%
|
7.87
|
| Current Deferred Liabilities |
|
96.80
-13.69%
|
112.16
+1.66%
|
110.33
+186891.53%
|
0.06
|
| Current Deferred Revenue |
|
96.80
-13.69%
|
112.16
+1.66%
|
110.33
+186891.53%
|
0.06
|
| Other Current Liabilities |
|
7.87
-37.30%
|
12.54
+1182.62%
|
0.98
-93.76%
|
15.68
|
| Total Non Current Liabilities Net Minority Interest |
|
103.07
+19.51%
|
86.24
-8.67%
|
94.43
+30.65%
|
72.28
|
| Long Term Debt And Capital Lease Obligation |
|
78.94
+0.90%
|
78.23
+9.59%
|
71.39
+13.45%
|
62.93
|
| Long Term Debt |
|
51.22
+16.43%
|
43.99
+54.65%
|
28.44
+109.62%
|
13.57
|
| Long Term Capital Lease Obligation |
|
27.73
-19.04%
|
34.24
-20.26%
|
42.95
-12.99%
|
49.36
|
| Long Term Provisions |
|
—
|
—
|
2.20
-7.95%
|
2.39
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
1.33
+19.19%
|
1.11
-49.32%
|
2.20
-7.95%
|
2.39
|
| Non Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.16
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
0.00
-100.00%
|
0.16
|
—
|
| Other Non Current Liabilities |
|
0.74
-16.33%
|
0.88
-93.15%
|
12.88
+85.04%
|
6.96
|
| Stockholders Equity |
|
75.90
-42.07%
|
131.03
+54.71%
|
84.69
-28.21%
|
117.97
|
| Common Stock Equity |
|
75.90
-42.07%
|
131.03
+54.71%
|
84.69
-28.21%
|
117.97
|
| Capital Stock |
|
5.90
+0.24%
|
5.89
+34.91%
|
4.37
+47.72%
|
2.96
|
| Common Stock |
|
5.90
+0.24%
|
5.89
+34.91%
|
4.37
+47.72%
|
2.96
|
| Share Issued |
|
100.34
+39.18%
|
72.09
+0.48%
|
71.75
+57.09%
|
45.68
|
| Ordinary Shares Number |
|
100.34
+39.18%
|
72.09
+0.48%
|
71.75
+57.09%
|
45.68
|
| Additional Paid In Capital |
|
437.44
-11.50%
|
494.29
-5.45%
|
522.78
-10.35%
|
583.12
|
| Retained Earnings |
|
-334.13
-1.37%
|
-329.61
+18.77%
|
-405.77
+7.68%
|
-439.50
|
| Gains Losses Not Affecting Retained Earnings |
|
-33.32
+15.73%
|
-39.54
-7.76%
|
-36.69
-28.26%
|
-28.61
|
| Minority Interest |
|
—
|
—
|
0.00
-100.00%
|
7.97
|
| Total Equity Gross Minority Interest |
|
75.90
-42.07%
|
131.03
+54.71%
|
84.69
-32.75%
|
125.94
|
| Total Capitalization |
|
127.12
-27.37%
|
175.02
+54.70%
|
113.14
-13.99%
|
131.54
|
| Working Capital |
|
90.49
-25.09%
|
120.80
+55.15%
|
77.86
-3.65%
|
80.81
|
| Invested Capital |
|
131.21
-27.05%
|
179.86
+52.04%
|
118.30
-13.34%
|
136.51
|
| Total Debt |
|
90.73
-0.80%
|
91.46
+7.53%
|
85.06
+12.25%
|
75.77
|
| Capital Lease Obligations |
|
35.43
-16.90%
|
42.63
-17.14%
|
51.45
-10.10%
|
57.23
|
| Net Tangible Assets |
|
75.37
-41.99%
|
129.92
+54.62%
|
84.02
-28.34%
|
117.25
|
| Tangible Book Value |
|
75.37
-41.99%
|
129.92
+54.62%
|
84.02
-28.34%
|
117.25
|
| Available For Sale Securities |
|
5.09
+71.60%
|
2.96
-7.26%
|
3.20
-21.55%
|
4.08
|
| Current Provisions |
|
1.17
+41.18%
|
0.83
-52.41%
|
1.74
+264.78%
|
0.48
|
| Derivative Product Liabilities |
|
22.06
+267.04%
|
6.01
-22.92%
|
7.80
|
0.00
|
| Financial Assets Designatedas Fair Value Through Profitor Loss Total |
|
0.00
-100.00%
|
4.56
-2.15%
|
4.66
-1.27%
|
4.72
|
| Foreign Currency Translation Adjustments |
|
-33.32
+15.73%
|
-39.54
-7.76%
|
-36.69
-28.26%
|
-28.61
|
| Investmentin Financial Assets |
|
5.09
-32.35%
|
7.52
-4.23%
|
7.85
-10.67%
|
8.79
|
| Other Equity Interest |
|
—
|
—
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-39.40
-271.39%
|
22.99
+192.90%
|
-24.75
+71.70%
|
-87.44
|
| Cash Flow From Continuing Operating Activities |
|
-39.40
-271.39%
|
22.99
+208.94%
|
-21.10
+69.35%
|
-68.84
|
| Cash From Discontinued Operating Activities |
|
0.00
|
0.00
+100.00%
|
-3.64
+80.41%
|
-18.60
|
| Net Income From Continuing Operations |
|
-67.59
-83.87%
|
-36.76
+68.54%
|
-116.83
-18.39%
|
-98.69
|
| Depreciation Amortization Depletion |
|
20.06
+1.09%
|
19.85
+7.14%
|
18.52
+0.48%
|
18.43
|
| Depreciation And Amortization |
|
20.06
+1.09%
|
19.85
+7.14%
|
18.52
+0.48%
|
18.43
|
| Other Non Cash Items |
|
34.94
+268.10%
|
-20.79
-217.03%
|
17.76
+105.88%
|
8.63
|
| Stock Based Compensation |
|
6.11
+92.93%
|
3.17
-39.48%
|
5.23
-13.40%
|
6.04
|
| Provisionand Write Offof Assets |
|
0.33
+117.81%
|
-1.88
-238.68%
|
1.35
+400.74%
|
0.27
|
| Deferred Tax |
|
-0.42
+21.52%
|
-0.54
-245.28%
|
0.37
+326.44%
|
0.09
|
| Deferred Income Tax |
|
-0.42
+21.52%
|
-0.54
-245.28%
|
0.37
+326.44%
|
0.09
|
| Operating Gains Losses |
|
0.34
+218.47%
|
-0.29
-3687.50%
|
0.01
-99.16%
|
0.95
|
| Net Foreign Currency Exchange Gain Loss |
|
0.34
+210.06%
|
-0.31
-3950.00%
|
0.01
+101.20%
|
-0.66
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-41.59
-177.50%
|
53.66
+9.84%
|
48.86
+953.71%
|
-5.72
|
| Change In Receivables |
|
-9.45
-120.61%
|
45.86
+1250.58%
|
-3.99
+55.68%
|
-8.99
|
| Changes In Account Receivables |
|
-5.02
-109.54%
|
52.60
+2235.52%
|
2.25
+170.66%
|
-3.19
|
| Change In Inventory |
|
—
|
—
|
0.00
|
0.00
|
| Change In Payables And Accrued Expense |
|
-3.26
-258.59%
|
2.06
+132.59%
|
-6.30
-294.18%
|
3.25
|
| Change In Payable |
|
-3.26
-258.59%
|
2.06
+132.59%
|
-6.30
-294.18%
|
3.25
|
| Change In Account Payable |
|
-3.26
-258.59%
|
2.06
+132.59%
|
-6.30
-294.18%
|
3.25
|
| Change In Other Working Capital |
|
-28.88
-602.49%
|
5.75
-90.28%
|
59.15
+257069.57%
|
0.02
|
| Investing Cash Flow |
|
-29.48
+71.32%
|
-102.81
-562.85%
|
-15.51
-461.75%
|
-2.76
|
| Cash Flow From Continuing Investing Activities |
|
-29.48
+71.32%
|
-102.81
-559.49%
|
-15.59
-573.39%
|
-2.31
|
| Cash From Discontinued Investing Activities |
|
0.00
|
0.00
-100.00%
|
0.08
+117.71%
|
-0.45
|
| Net PPE Purchase And Sale |
|
-2.36
+8.63%
|
-2.58
-140.73%
|
-1.07
+55.86%
|
-2.43
|
| Purchase Of PPE |
|
-2.36
+8.63%
|
-2.58
-140.73%
|
-1.07
+55.86%
|
-2.43
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-3.53
+8.07%
|
-3.84
-258.15%
|
-1.07
+56.04%
|
-2.44
|
| Net Investment Purchase And Sale |
|
-25.95
+73.78%
|
-98.96
-668.71%
|
-12.87
-10317.46%
|
0.13
|
| Purchase Of Investment |
|
-159.78
+1.84%
|
-162.77
-1118.06%
|
-13.36
|
0.00
|
| Sale Of Investment |
|
133.83
+109.74%
|
63.81
+12948.26%
|
0.49
+288.10%
|
0.13
|
| Net Intangibles Purchase And Sale |
|
-1.17
+6.90%
|
-1.26
|
0.00
+100.00%
|
-0.01
|
| Purchase Of Intangibles |
|
-1.17
+6.90%
|
-1.26
|
0.00
+100.00%
|
-0.01
|
| Net Other Investing Changes |
|
-0.00
+0.00%
|
-0.00
+99.94%
|
-1.64
|
—
|
| Financing Cash Flow |
|
-16.76
-118.81%
|
89.11
+7.54%
|
82.86
+7137.12%
|
1.15
|
| Cash Flow From Continuing Financing Activities |
|
-16.76
-118.81%
|
89.11
+9.90%
|
81.08
+1180.40%
|
-7.50
|
| Net Issuance Payments Of Debt |
|
-16.19
-326.86%
|
7.14
-47.05%
|
13.48
+304.12%
|
-6.60
|
| Issuance Of Debt |
|
0.00
-100.00%
|
23.20
-21.81%
|
29.67
+416.02%
|
5.75
|
| Repayment Of Debt |
|
-16.19
-0.81%
|
-16.06
+0.79%
|
-16.19
-31.06%
|
-12.35
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
23.20
-21.81%
|
29.67
+416.02%
|
5.75
|
| Long Term Debt Payments |
|
-16.19
-0.81%
|
-16.06
+0.79%
|
-16.19
-31.06%
|
-12.35
|
| Net Long Term Debt Issuance |
|
-16.19
-326.86%
|
7.14
-47.05%
|
13.48
+304.12%
|
-6.60
|
| Net Common Stock Issuance |
|
0.04
-99.95%
|
82.82
+21.91%
|
67.94
+12039.54%
|
-0.57
|
| Common Stock Payments |
|
—
|
—
|
—
|
-0.57
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
-0.57
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
0.00
|
—
|
| Changes In Cash |
|
-85.65
-1021.42%
|
9.29
-78.18%
|
42.61
+147.84%
|
-89.06
|
| Effect Of Exchange Rate Changes |
|
3.93
+242.73%
|
-2.75
-411.31%
|
0.88
+126.31%
|
-3.36
|
| Beginning Cash Position |
|
143.25
+4.79%
|
136.71
+46.66%
|
93.22
-49.79%
|
185.64
|
| End Cash Position |
|
61.53
-57.05%
|
143.25
+4.79%
|
136.71
+46.66%
|
93.22
|
| Free Cash Flow |
|
-42.93
-324.25%
|
19.15
+174.15%
|
-25.82
+71.28%
|
-89.89
|
| Common Stock Issuance |
|
0.04
-99.95%
|
82.82
+21.91%
|
67.94
|
—
|
| Interest Paid CFF |
|
-0.61
+27.74%
|
-0.85
-154.35%
|
-0.33
-0.30%
|
-0.33
|
| Interest Paid CFO |
|
—
|
—
|
—
|
1.16
|
| Interest Received CFO |
|
8.43
+28.51%
|
6.56
+80.81%
|
3.63
+213.21%
|
1.16
|
| Issuance Of Capital Stock |
|
0.04
-99.95%
|
82.82
+21.91%
|
67.94
|
—
|
| Taxes Refund Paid |
|
-0.01
|
—
|
—
|
—
|
| Cash From Discontinued Financing Activities |
|
0.00
|
0.00
-100.00%
|
1.78
-79.41%
|
8.65
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|